Alterations in the gene encoding fibroblast growth factor receptor (FGFR) ... and skin or nail events (in 2 patients each). A dose reduction was required in 55 patients.

Another FGFR Inhibitor Active in Bile Duct Cancers ... (91%), nail toxicity (47%), increased liver enzymes (27%), and palmar-plantar erythrodysesthesia (21%).

PURPOSEMultiple FGFR inhibitors are currently in clinical trials enrolling adults with different solid tumors, ... vision changes, and skin and nail changes. 14 To decrease toxicity and address the ...

Co-lead author of the study, Dr. Volker Hovestadt, explained, "We discovered that FGFR and NOTCH receptors are expressed by proliferative NSC-like cells, while more differentiated malignant cells ...

Gain-of-function mutations in fibroblast growth factor receptor (FGFR) genes are known to cause a range of skeletal disorders, such as craniosynostosis and chondrodysplasia, which severely affect ...

Futibatinib demonstrated clinical benefit among previously treated patients with fibroblast growth factor receptor 2 fusion- or rearrangement-positive intrahepatic cholangiocarcinoma, according to ...

Drugs targeting FGFR mutations, which are seen in patients with intrahepatic cholangiocarcinoma (CCA), have generated particular excitement; the authors note that prior to the approval of ...

A new study explores the potential of fibroblast growth factor receptor (FGFR) antagonists in restoring defective mandibular bone repair in mouse models of osteochondrodysplasia, a group of ...

Erdafitinib is a pan–fibroblast growth factor receptor (FGFR) inhibitor approved for the treatment of locally advanced or metastatic urothelial carcinoma in adults with susceptible FGFR3/2 ...

Gain-of-function mutations in fibroblast growth factor receptor (FGFR) genes are known to cause a range of skeletal disorders, such as craniosynostosis and chondrodysplasia, which severely affect ...